KOL Pulse AI
@KolPulseAI
Instant insights from oncology’s top voices. Download the free Chrome Extension that tracks trials, sentiment & influence on X. h
Check KOL Conflicts of Interest directly in your X timeline! Get the KOL Pulse Chrome Extension Today! chromewebstore.google.com/detail/kol-pul…
CAR-T and bispecifics are powerful, life-prolonging tools, but their success depends heavily on timing, disease context, and the ability to debulk beforehand. The field truly needs innovation beyond the current immunotherapy paradigm.
I am scared of using CART or bispecifics in myeloma with large volume disease: CRS, neurotoxicity, HLH, risk of death, and all kinds of complications are much higher. I’d rather control myeloma and get it to low volume before using these immunotherapy treatments. This is why…
The global, regional, and national burden of cancer, 1990–2023, with forecasts to 2050: a systematic analysis for the Global Burden of Disease Study 2023 @TheLancet doi.org/10.1016/S0140-… 👉increasing numbers of cases and deaths forecasted up to 2050
🔥off the press🔥 Navigating second-line therapy after immunotherapy in advanced HCC @JHEP_Reports doi.org/10.1016/j.jhep… 👉Multiple options in first and second line 😅Our thoughts on how to best sequence @myESMO @EASLedu @ILCAnews
MRD vs No MRD guided treatment for Myeloma: A great debate b/w @szusmani (yes) vs @End_myeloma (no) and discussion by @VincentRK on MRD driven treatment in Multiple Myeloma Kyle Barlogie Plasma Cell Disorders Symposium #MMSM #MedTwitter #MedEd #AgreeToAgree
AI product adoption is fast.
Managing breast cancer in young #BRCA carriers remains a complex and evolving challenge. In our latest review led by @RobertoBoreaMD and @matteolambe we discuss how genetics, fertility, and survivorship intertwine, and why multidisciplinary approach is🔑! @OncoAlert
Managing #breastcancer in young #BRCA carriers women is uniquely complex. Our review highlights the critical need for a personalized, multidisciplinary approach to optimize treatment, long-term outcomes, and toxicities ➡️pmc.ncbi.nlm.nih.gov/articles/PMC12… @matteolambe @Lucarecco
How I manage MGUS in one Figure 👇
Management of Monoclonal Gammopathy of Undetermined Significance. In low-risk patients who are younger than 50 years of age, bone marrow biopsy and imaging may be considered a baseline evaluation, given the anticipated life expectancy. Learn more: nej.md/473uOsj
Deep congratulations to Dr. @DavidRSpigel, the incoming Sarah Cannon President and Chief Medical Officer, Dr. @MLJohnsonMD2, the incoming Chief Scientific Officer, and Dr. @ErikaHamilton9 the incoming Chief Development Officer! What a powerhouse team! scri.com/news/scri-anno…
Amazing question to leadership panel: “if you had a magic 🪄 what would you change?” - access to screening -PBMs -more cost efficiency, no prior auth! Price control - embrace health technology #ASCOQLTY25
Using #patientnavigation to consent and collect liquid biopsy PRIOR to initial consult: 1) expedites treatment plans 2) provides connection and support for patients early on 3) improves patient satisfaction @lungoncdoc @MDAndersonNews @ASCO #ASCOQLTY25
✈️ On my way to #ASCOQLTY25! Excited to present our @MDAndersonNews LUNG-FAST pilot: can pre-visit liquid biopsy streamline and improve lung cancer care? Stay tuned! @ASCO
🔬 At a glance: The 20 breakthrough abstracts shaping #ESMO2025. A concise visual guide to the studies you’ll want to check first — from lung to pancreas, from adjuvant to late-line. 📍Berlin | Oct 17–21 | #Oncology #CancerResearch #ESMO25
Starting our EMBRACE Forum Series for patients with major MBC updates for our patients @DFCI_BreastOnc with @nlinmd and @stolaney1 .
The evolving, confusing 1st line questions in HER2+ MBC
The most practice changing line up that I have ever seen at one meeting! So excited for my first ESMO.
One week to #ESMO25. An unprecedented ESMO conference. Seven positive press releases, anticipating the expansion of T-DXd to the curative setting, two Trop2 ADCs reaching first-line mTNBC, 2 novel ET-based combos, adjuvant CDK4/6i improving OS. See you in Berlin! #ESMOAmbassadors
In anticipation of #esmo2025 please find a perfect summary of #bladdercancer trials made by our @UroOnc fellow superstar @hjwang26 .. looking forward to 📊🧑💻 ALBAN, POTOMAC @IBCG_BladderCA @CleClinicUro ..
FDA Approval Alert (Oct 8, 2025): FDA approves cemiplimab-rwlc (Libtayo) for adjuvant treatment of cutaneous SCC at high risk of recurrence after surgery & radiation. Cemiplimab cut recurrence risk by 68% (HR 0.32; p<0.0001). @Larvol fda.gov/drugs/resource…
Amazing paper
Just out in the Journal of Clinical Oncology! @JCO_ASCO A paradigm changing paper on MGUS and Smoldering Myeloma @FrancescoMaura4 And it’s Open Access!! ascopubs.org/doi/10.1200/JC… KEY FINDINGS: 1) We identify for the first time myeloma defining genomic events to differentiate…
Unresectable stage III non-small-cell lung cancer: state of the art and challenges Great review👇 nature.com/articles/s4157…
Let me introduce you to the typical patient who is able to meet all 40 or so cancer clinical trial eligibility criteria of a usual sponsored trial + allow me to bring to your attention this great paper by @bherzbergmd (open access) highlighting the very restrictive nature of…
United States Trends
- 1. Lions 57.2K posts
- 2. Lions 57.2K posts
- 3. Butker 6,746 posts
- 4. Goff 9,886 posts
- 5. #TNABoundForGlory 22.1K posts
- 6. Baker 46.6K posts
- 7. #OnePride 4,142 posts
- 8. Kelce 9,397 posts
- 9. #SNFonNBC N/A
- 10. #DETvsKC 2,498 posts
- 11. Cal Raleigh 3,281 posts
- 12. 49ers 41.8K posts
- 13. #RHOP 10.1K posts
- 14. Dan Campbell 1,709 posts
- 15. Leon Slater 1,568 posts
- 16. Ty Dillon 1,093 posts
- 17. Bucs 14.5K posts
- 18. Gausman 2,359 posts
- 19. Gibbs 4,455 posts
- 20. Denny 5,513 posts
Something went wrong.
Something went wrong.